SORAFENIB

作品数：318被引量：1563H指数：18
导出分析报告
相关领域：医药卫生更多>>
相关作者：曾普华郜文辉刘霞孙惠川汤钊猷更多>>
相关机构：湖南中医药大学福建医科大学中山大学复旦大学更多>>
相关期刊：更多>>
相关基金：国家自然科学基金中国博士后科学基金广东省自然科学基金国家重点基础研究发展计划更多>>
-
在结果中检索

检索结果分析

结果分析中...
选择条件：
  • 期刊=Signal Transduction and Targeted Therapyx
共 条 记 录，以下是1-8
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study被引量：1
《Signal Transduction and Targeted Therapy》2023年第10期4903-4913,共11页Ruoyang Shao Yu Zhang Jinping He Fen Huang Zhiping Fan Kaibo Yang Yajing Xu Na Xu Yi Luo Lan Deng Xi Zhang Jia Chen Mingzhe Han Xudong Li Sijian Yu Hui Liu Xinquan Liang Xiaodan Luo Pengcheng Shi Zhixiang Wang Ling Jiang Xuan Zhou Ren Lin Yan Chen Sanfang Tu Jing Sun Yu Wang Qifa Liu Li Xuan 
This work was supported by the National Natural Science Foundation of China(82170213 to L.X.,81970161 to Q.L.);the National Key Research and Development Projects of China(2021YFC2500301-4 to Q.L.,2022YFC2502600-5 to L.X.);Clinical Research Program of Nanfang Hospital,Southern Medical University(2021CR002 to L.X.).
Sorafenib therapy improves overall survival(OS)in patients with FLT3 internal tandem duplication(ITD)acute myeloid leukemia(AML)undergoing allogeneic hematopoietic stem cell transplantation.We explored the efficacy of...
关键词：HEMATOPOIETIC SORAFENIB PATIENTS 
UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGCip in hepatocellular carcinoma被引量：9
《Signal Transduction and Targeted Therapy》2021年第6期1856-1868,共13页Junjie Xu Lin Ji Yeling Ruan Zhe Wan Zhongjie Lin Shunjie Xia Liye Tao Junhao Zheng Liuxin Cai Yifan Wang Xiao Liang Xiujun Cai 
supported by the National Natural Science Foundation of China under No.81827804(to C.X.),Grant No.81772546(to C.X.),No.81902367(to XJ.),and No.82072625(to L.X.);China Postdoctoral Science Foundation under Grant No.2020M671755(to X.J.);Natural Science Foundation of Zhejiang Province under Grant No.LY15H160014(to C.L.);Zhejiang Clinical Research Center of Minimally Invasive Diagnosis and Treatment of Abdominal Diseases under Grant No.2018E50003(to C.X.);Key Research and Development Project of Zhejiang Province under Grant No.2018C03083(to C.X.),and 2020C03122(to W.Y.);Health innovation Talent Support Project of Zhejiang Medical and Health Science and Technology Plan under Grant No.2021447581(to XJ.).
The treatment for hepatocellular carcinoma(HCC)is promising in recent years,but still facing critical challenges.The first targeted therapy,sorafenib,prolonged the overall survival by months.However,resistance often o...
关键词：HOMEOSTASIS RESISTANCE OVERCOME 
CircRNA-SORE mediates sorafenib resistance inhepatocellular carcinoma by stabilizing YBX1
《Signal Transduction and Targeted Therapy》2021年第1期117-130,共14页Junjie Xu Lin Ji Yuelong Liang Zhe Wan Wei Zheng Xiaomin Song Kirill Gorshkov Qiming Sun Hui Lin Xueyong Zheng Jiang Chen Ren-an Jin Xiao Liang Xiujun Cai 
This research was supported by the National Natural Science Foundation of China under Grant No.81772546(to X.C.),No.81827804(to X.C.)and No.81902367(to J.X.);Zhejiang Provincial Natural Science Foundation of China under Grant No.LQ19H160026(to J.X.)and LGF18H160011(to Y.L.);China Postdoctoral Science Foundation under Grant No.2020M671755(to J.X.);Key Research and Development Project of Zhejiang Province under Grant No.2018C03083(to X.C.);Zhejiang Clinical Research Center of Minimally Invasive Diagnosis and Treatment of Abdominal Diseases under Grant No.2018E50003(to X.C.);Special fund for basic scientific research operating expenses of Zhejiang University under Grant No.2019XZZX005-4-05(to Y.L.);Hepatobiliary and Pancreatic Cancer Research of Hubei Chen Xiaoping Science and Technology Development Foundation under Grant No.CXPJJH11900001-2019308(to J.X.),CXPJJH11900001-2019209(to X.L.)and CXPJJH11900009-03(to X.L.).
Sorafenib is the first-line chemotherapeutic therapy for advanced hepatocellular carcinoma(HCC).However,sorafenib resistance significantly limits its therapeutic efficacy,and the mechanisms underlying resistance have ...
关键词：SORAFENIB HEPATOCELLULAR RESISTANCE 
m6A RNA methylation-mediated HNF3γ reduction rendershepatocellular carcinoma dedifferentiation and sorafenibresistance
《Signal Transduction and Targeted Therapy》2021年第1期144-157,共14页Tengfei Zhou Shichao Li Daimin Xiang Junyu Liu Wen Sun Xiuliang Cui Beifang Ning Xiao Li Zhuo Cheng Weiqi Jiang Cheng Zhang Xijun Liang Liang Li Xin Cheng Liu Hui Hongyang Wang Jin Ding 
This work was supported by Ministry of Education(MOE)Key Laboratory on Signaling Regulation and Targeting Therapy of Liver Cancer and Shanghai Key Laboratory of Hepatobiliary Tumor Biology;This work was supported by grants from the National Natural Science Foundation of China 81972222,81772582,and 81702736;National Key R&D Program of China(2017YFA0504503);Program of Shanghai Academic Research Leader(18XD1405400).
Hepatocyte nuclear factor 3γ(HNF3γ)is a hepatocyte nuclear factor,but its role and clinical significance in hepatocellular carcinoma(HCC)remain unclear.Herein,we report that HNF3γexpression is downregulated in pati...
关键词：SORAFENIB HEPATOCELLULAR MEDIATED 
BARMR1-mediated sorafenib resistance is derived through stem-like property acquisition by activating integrin-FAK signaling pathways
《Signal Transduction and Targeted Therapy》2020年第1期1623-1625,共3页Xing Rong Guo Meng Ye Shan Yu Huang Zong Li Zhang Yue Yuan Long Jun Dai Jue Wang Xue Peng Zhou Fu Yun Ji Jun Ming Tang Zhong Ji Meng Xu Zhi Ruan 
supported by the National Natural Science Foundation of China(No.81700769,81641028,81602297);the Hubei Science&Technology Department Foundation(2016ACA157,2018ACA162);the Biomedical Research Foundation,Hubei University of Medicine(HBMUPI201803);the Cultivating Project for Young Scholars at Hubei University of Medicine(2016QDJR02);the Innovative Research Program for Graduates of Hubei University of Medicine(YC2019003,YC2019008).
Dear Editor,BARMR1(alternatively named FAM92A1 or FAM92A)gene was first identified in 2002 and is a highly conserved gene and widely expressed in most tissues in mammals.1 We first cloned the complete CDS sequence of ...
关键词：inflammation property RESISTANCE 
The mechanisms of sorafenib resistance in hepatocellular carcinoma:theoretical basis and therapeutic aspects被引量：90
《Signal Transduction and Targeted Therapy》2020年第1期1713-1727,共15页Weiwei Tang Ziyi Chen Wenling Zhang Ye Cheng Betty Zhang Fan Wu Qian Wang Shouju Wang Dawei Rong F.P.Reiter E.N.De Toni Xuehao Wang 
supported by grants from the National Natural Science Key Foundation of China(grant No.81530048);the National Natural Youth Fund(grant No.81902485).
Sorafenib is a multikinase inhibitor capable of facilitating apoptosis,mitigating angiogenesis and suppressing tumor cell proliferation.In late-stage hepatocellular carcinoma(HCC),sorafenib is currently an effective f...
关键词：SORAFENIB THERAPEUTIC HEPATOCELLULAR 
m6A RNA methylation-mediated HNF3γreduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance被引量：13
《Signal Transduction and Targeted Therapy》2020年第1期36-49,共14页Tengfei Zhou Shichao Li Daimin Xiang Junyu Liu Wen Sun Xiuliang Cui Beifang Ning Xiao Li Zhuo Cheng Weiqi Jiang Cheng Zhang Xijun Liang Liang Li Xin Cheng Liu Hui Hongyang Wang Jin Ding 
supported by Ministry of Education(MOE)Key Laboratory on Signaling Regulation and Targeting Therapy of Liver Cancer and Shanghai Key Laboratory of Hepatobiliary Tumor Biology;supported by grants from the National Natural Science Foundation of China 81972222,81772582,and 81702736,National Key R&D Program of China(2017YFA0504503);Program of Shanghai Academic Research Leader(18XD1405400).
Hepatocyte nuclear factor 3γ(HNF3γ)is a hepatocyte nuclear factor,but its role and clinical significance in hepatocellular carcinoma(HCC)remain unclear.Herein,we report that HNF3γexpression is downregulated in pati...
关键词：SORAFENIB HEPATOCELLULAR MEDIATED 
CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1被引量：36
《Signal Transduction and Targeted Therapy》2020年第1期50-63,共14页Junjie Xu Lin Ji Yuelong Liang Zhe Wan Wei Zheng Xiaomin Song Kirill Gorshkov Qiming Sun Hui Lin Xueyong Zheng Jiang Chen Ren-an Jin Xiao Liang Xiujun Cai 
supported by the National Natural Science Foundation of China under Grant No.81772546(to X.C.),No.81827804(to X.C.)and No.81902367(to J.X.);Zhejiang Provincial Natural Science Foundation of China under Grant No.LQ19H160026(to J.X.)and LGF18H160011(to Y.L.);China Postdoctoral Science Foundation under Grant No.2020M671755(to J.X.);Key Research and Development Project of Zhejiang Province under Grant No.2018C03083(to X.C.);Zhejiang Clinical Research Center of Minimally Invasive Diagnosis and Treatment of Abdominal Diseases under Grant No.2018E50003(to X.C.);Special fund for basic scientific research operating expenses of Zhejiang University under Grant No.2019XZZX005-4-05(to Y.L.);Hepatobiliary and Pancreatic Cancer Research of Hubei Chen Xiaoping Science and Technology Development Foundation under Grant No.CXPJJH11900001-2019308(to J.X.);CXPJJH11900001-2019209(to X.L.);CXPJJH11900009-03(to X.L.).
Sorafenib is the first-line chemotherapeutic therapy for advanced hepatocellular carcinoma(HCC).However,sorafenib resistance significantly limits its therapeutic efficacy,and the mechanisms underlying resistance have ...
关键词：SORAFENIB HEPATOCELLULAR RESISTANCE 
全选清除导出
共1页<1>
检索报告 对象比较 聚类工具 使用帮助 返回顶部